The recent FLOW trial with semaglutide in patients with chronic kidney disease and T2DM, with a composite of major kidney disease events as the primary outcome, showed significant reductions in both cardiovascular mortality (HR 0.71
Notably, the periventricular white matter, thalamus, and brainstem were unaffected, which is a typical MRI manifestation of L2HGA
Get Your GLP-1 In 4 Easy Steps TampaGLP1.com is designed for convenience, affordability and comfort
Participants taking the highest maintenance dose experienced weight reductions comparable to some injectable GLP-1 agents, though the timeline to reach therapeutic doses extended over several months
On the other hand, compounded drugs are not subject to the same kind of regulation and do not require FDA approval